Despite technological and medical advances the survival rates for many cancers remain poor.

‘Despite technological and medical advances the survival rates for many cancers remain poor, partly due to the inability to cancer at an early stage and then a targeted treatment, ‘said Professor Duan said.

Current cancer treatments destroy the cells that form the bulk of the tumor, but largely ineffective against detect the root of the cancer, the cancer stem cells, suggesting to have a cure for cancer and we provide exactly. Eliminating the cancer stem cells. . ‘This could ultimately lead to a better survival rate for cancer and greatly improved quality of life for patients.Buy now Drug Discovery Foundation Fund history from clinical testing for Alzheimer’s disease.

The AD Drug Discovery Foundation assigned the British company Cambridge Cognition Ltd is allowance of $ 200,000 in its development of a clinical cognitive Rating product for the Alzheimer supporting disease.

Cambridge Cognition is a worldwide leader in development of computerized cognitive Reviews, his CANTAB battery, which are now deployed in more than 500 research units in 60 countries. Her pair of associations learning assay most precise the most accurate actual test in the detection of the early dementias as well mild cognitive impairment, and accurately difference between dementia and normal patients and those suffering from depression. Disease modifying which basis for future clinical assessment of AD.